Nouscom raised $135 million in an oversubscribed Series D round to accelerate NOUS-209, its off-the-shelf neoantigen-based immunotherapy for cancer interception. The company’s lead focus is a global registration-enabling clinical trial in Lynch syndrome carriers, aiming to prevent progression to advanced adenomas or colorectal cancer. The FDA granted Fast Track designation to the program, and Nouscom plans to push development toward a Phase 2 study. The financing co-led by M Ventures and Revelation Partners also brought in Angelini Industries and funding from the European Investment Bank through a co-investment facility. At a scientific level, Nouscom’s program is tied to long-term follow-up results expected to be unveiled at ESMO, where the company previously reported that evaluable Lynch syndrome carriers receiving NOUS-209 remained free of advanced adenomas and colorectal cancer at one and two years in the Phase Ib/II trial cohort. For investors and biotech strategists, the round reinforces continued institutional appetite for prevention-oriented immunotherapy, especially when tied to identifiable genetic risk populations.